Clinicopathological characteristics | N | VEGF-C positive | P | VEGF-C mRNA expression level | P | |
---|---|---|---|---|---|---|
 |  | N | rate (%) |  |  |  |
Age (years) | Â | Â | Â | Â | Â | Â |
<60 | 30 | 23 | 76.7 |  | 2.41 ± 0.33 |  |
≥ 60 | 11 | 10 | 90.9 | 0.412 | 3.20 ± 0.76 | 0.505 |
Histological grade (invasive ductal) | Â | Â | Â | Â | Â | Â |
I+II | 16 | 14 | 87.5 |  | 2.72 ± 0.58 |  |
III+IV | 20 | 14 | 70.0 | 0.257 | 2.65 ± 0.45 | 0.908 |
Tumor size | Â | Â | Â | Â | Â | Â |
T1 | 15 | 12 | 80.0 |  | 3.00 ± 0.63 |  |
T2 | 23 | 18 | 78.3 |  | 2.14 ± 0.31 |  |
T3 | 3 | 3 | 100 | 0.670 | 4.58 ± 1.68 | 0.237 |
Lymph nodal status | Â | Â | Â | Â | Â | Â |
N0 | 22 | 20 | 90.9 |  | 2.92 ± 0.48 |  |
N1 | 12 | 8 | 66.7 |  | 2.10 ± 0.53 |  |
N2 | 5 | 3 | 60.0 |  | 2.51 ± 0.86 |  |
N3 | 2 | 2 | 100 | 0.606 | 2.65 ± 0.07 | 0.710 |
Estrogen receptor status | Â | Â | Â | Â | Â | Â |
- | 10 | 9 | 90.0 |  | 2.42 ± 0.63 |  |
+~+++ | 31 | 24 | 77.4 | 0.653 | 2.69 ± 0.38 | 0.606 |
Progesterone receptor status | Â | Â | Â | Â | Â | Â |
- | 8 | 6 | 75.0 |  | 2.14 ± 0.75 |  |
+~+++ | 33 | 27 | 81.8 | 0.642 | 2.75 ± 0.35 | 0.217 |
HER2/neu score | Â | Â | Â | Â | Â | Â |
- (0-1) | 13 | 10 | 76.9 |  | 2.70 ± 0.66 |  |
+ (2-3) | 28 | 23 | 82.1 | 0.693 | 2.60 ± 0.36 | 0.918 |